Composite for treating hyperlipidemia

A technology of hyperlipidemia and composition, applied in the field of new composition, which can solve problems that do not involve the optimal ratio of acipimox and fluvastatin

Inactive Publication Date: 2005-11-09
LUNAN PHARMA GROUP CORPORATION
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Chinese patent application CN1425374A discloses the composition of acipimox and lovastatin, the disclosed ratio is that the weight ratio of acipimox and lovastatin is 25~50:1, and the preferred ratio is 25:1 or 37.5:1 , but did not involve the optimal ratio of acipimox and fluvastatin compound and the corresponding pharmacological experimental data

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0016] a. Acipimox 200g

[0017] Blank ball core 250g

[0018] 7% PVP solution (solvent is 90% ethanol) 200g

[0019] Preparation process: Pass acipimox through a 120-mesh sieve, weigh the prescription amount, and pour it into the lower hopper. Turn on the granulation coating machine, the air inlet pressure is 0.5bar, the air inlet temperature is 30°C, the spray gun pressure (CYL) is 3bar, the atomization pressure (CAP1) is 0.8bar, pour blank ball cores, granulate, the feeding speed is 4rpm, the creeping Pump 12%, turntable speed 145rpm, spray 7% PVP solution (solvent is 90% ethanol). After granulation is completed, dry at 50°C and discharge.

[0020] b. Fluvastatin sodium 10g (calculated as fluvastatin free acid)

[0021] Blank ball core 30g

[0022] 7% PVP solution (solvent is 90% ethanol) 30g

[0023] Preparation process: pass fluvastatin sodium through a 120-mesh sieve, weigh the prescription amount, and pour it into the lower hopper. Start the granulati...

example 2

[0026] a. Acipimox 200g

[0027] Lactose 30g

[0028] Sodium carboxymethyl starch 30g

[0029] Microcrystalline Cellulose 18g

[0030] 6% PVP in absolute ethanol 100g

[0031] Magnesium Stearate 2g

[0032] Preparation process: Acipimox is passed through a 100-mesh sieve, lactose, sodium carboxymethyl starch, and microcrystalline cellulose are passed through a 80-mesh sieve, and the prescribed amount of acipimox, lactose, sodium carboxymethyl starch, and microcrystalline cellulose is weighed Mix the ingredients evenly, add an appropriate amount of 6% PVP absolute ethanol solution to granulate, dry at 60°C, sieve the dry granules with a 16-mesh sieve, and add the prescribed amount of magnesium stearate to the dry granules.

[0033] b. Fluvastatin sodium 20g (calculated as fluvastatin free acid)

[0034] Hydroxypropyl Cellulose 30g

[0035] 20g pregelatinized starch

[0036] 6% PVP in absolute ethanol solution 30g

[0037]Glyceryl Behenate 1g

[...

example 3

[0041] a. Acipimox 200g

[0042] Lactose 30g

[0043] Sodium carboxymethyl starch 30g

[0044] Microcrystalline Cellulose 18g

[0045] 6% PVP in absolute ethanol 100g

[0046] Magnesium Stearate 2g

[0047] Preparation process: Acipimox is passed through a 100-mesh sieve, lactose, sodium carboxymethyl starch, and microcrystalline cellulose are passed through a 80-mesh sieve, and the prescribed amount of acipimox, lactose, sodium carboxymethyl starch, and microcrystalline cellulose is weighed Mix the ingredients evenly, add an appropriate amount of 6% PVP absolute ethanol solution to granulate, dry at 60°C, sieve the dry granules with a 16-mesh sieve, and add the prescribed amount of magnesium stearate to the dry granules.

[0048] b. Fluvastatin sodium 30g (calculated as fluvastatin free acid 30g)

[0049] Hydroxypropyl Cellulose 50g

[0050] 40g pregelatinized starch

[0051] 6% PVP in absolute ethanol solution 50g

[0052] Glyceryl Behenate...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
Login to view more

Abstract

The present invention provides a drug composite for treating hyperlipidemia, the characteristics of which lies in containing effective amount Acipimox and Fluvastatin natrium, the weight ratio is (5~30):1, the optimal selection weight ratio is (5~15):1, the further optimal selection weight ratio is 10:1. The lipid-lowering effect is superior to the simple recipe with same dose significantly, which shows that there is synergistic effect and no distinct toxicity function under taking the Acipimox and the Fluvastatin both.

Description

Technical field [0001] The invention relates to a new composition for treating hyperlipidemia, especially a composition containing Acipimox, Fluvastatin salt and pharmaceutical auxiliary materials. Background technique [0002] With the continuous development of medical science, people realize that the high content of cholesterol and fat is the basic cause of cardiovascular disease, and hyperlipidemia is the main risk factor of coronary heart disease and hypertension. Therefore, people began to focus on the development of blood lipid regulating drugs as the prevention and treatment of cardiovascular diseases. Since the late 1980s, a large number of blood lipid-lowering drugs have been launched, among which statins have been well received by people, and their clinical efficacy is unmatched by other types of blood lipid regulating drugs. Over the past ten years, the completion of several international large-scale coronary heart disease prevention and treatment trials has conf...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4965
Inventor 赵志全
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap